Medicare Enrolled

Dr. Tareq Abou-Khamis, M.D.

Rheumatology · Houston, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
2500 FONDREN RD, Houston, TX 77063
7132735805
In practice since 2007 (18 years)
NPI: 1851587612 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Abou-Khamis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abou-Khamis? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Abou-Khamis

Dr. Tareq Abou-Khamis is a rheumatology in Houston, TX, with 18 years in practice. Based on federal Medicare data, Dr. Abou-Khamis performed 97,658 Medicare services across 852 unique beneficiaries.

Between the years covered by Open Payments, Dr. Abou-Khamis received a total of $174,240 from 43 pharmaceutical and/or device companies across 1098 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Abou-Khamis is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 16% volume in TX$ $174,240 industry payments

Medicare Practice Summary

Medicare Utilization ↗
97,658
Medicare services
Top 16% in TX for rheumatology
852
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,425 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)82,400$4$30
Abatacept infusion (Orencia)12,475$34$80
Denosumab injection (Prolia/Xgeva)1,020$19$70
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle403$56$218
Office visit, established patient (30-39 min)282$94$156
Blood draw (venipuncture)167$8$11
Complete blood count (CBC) with differential146$8$26
Comprehensive metabolic blood panel131$10$50
Administration of chemotherapy into vein, 1 hour or less120$106$600
C-reactive protein test (inflammation marker)111$5$29
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less108$52$230
Office visit, established patient (20-29 min)96$62$114
Sed rate test (inflammation marker)38$3$21
Vitamin D level test26$29$125
Drug injection, under skin or into muscle24$11$70
Urinalysis with microscopic exam21$3$20
New patient office visit (45-59 min)20$124$240
Thyroid stimulating hormone (TSH) test16$16$47
Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment15$49$300
X-ray lower and sacral spine, minimum of 6 views14$47$225
New patient office visit (30-44 min)14$82$165
Creatine kinase (cardiac enzyme) level, total11$6$26
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.9% high complexity
86.0% medium
1.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$174,240
Total received (2018-2024)
Avg $24,891/year across 7 years
Top 5% in TX for rheumatology
43
Companies
1,098
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$154,948 (88.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,009 (8.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,282 (2.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,937
2023
$2,832
2022
$2,217
2021
$4,060
2020
$18,485
2019
$84,721
2018
$59,987

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$65,844
Mallinckrodt Enterprises LLC
$58,591
Amgen Inc.
$19,144
Mallinckrodt LLC
$10,790
Janssen Biotech, Inc.
$3,446
AstraZeneca Pharmaceuticals LP
$2,696
UCB, Inc.
$2,511
Mallinckrodt Hospital Products Inc.
$2,023
Lilly USA, LLC
$1,194
E.R. Squibb & Sons, L.L.C.
$1,156
AbbVie Inc.
$1,052
Novartis Pharmaceuticals Corporation
$1,031
ABBVIE INC.
$742
PFIZER INC.
$681
GENZYME CORPORATION
$675
AbbVie, Inc.
$455
GlaxoSmithKline, LLC.
$405
Horizon Therapeutics plc
$296
Genentech USA, Inc.
$277
Aurinia Pharma U.S., Inc.
$182
Horizon Pharma plc
$173
Sobi, Inc
$77
Fresenius Kabi USA, LLC
$76
Boehringer Ingelheim Pharmaceuticals, Inc.
$72
Radius Health, Inc.
$70
MEDEXUS PHARMA, INC.
$69
Hikma Pharmaceuticals USA
$69
TerSera Therapeutics LLC
$63
Alexion Pharmaceuticals, Inc.
$52
Actelion Pharmaceuticals US, Inc.
$48
American Regent
$29
West-Ward Pharmaceuticals
$29
ANI Pharmaceuticals, Inc.
$27
MEDAC PHARMA, INC.
$26
SANOFI-AVENTIS U.S. LLC
$24
Alvogen Inc
$24
Kiniksa Pharmaceuticals, Ltd.
$22
Sandoz Inc.
$19
Celltrion USA Inc.
$17
Takeda Pharmaceuticals U.S.A., Inc.
$17
Kyowa Kirin, Inc.
$16
ARBOR PHARMACEUTICALS, INC.
$16
Zyla Life Sciences
$14
Top 3 companies account for 82.4% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUEXIS · ELIQUIS · EVENITY · EVUSHELD · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Horizant · Humira · IDACIO · INJECTAFER · KEVZARA · KRYSTEXXA · Kineret · LUPKYNIS · Mitigare · OPSUMIT · ORENCIA · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · Quzyttir · RAYOS · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · STRENSIQ · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · Uloric · VIMOVO · XELJANZ · YUFLYMA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (89%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for rheumatology in TX.

Equivalent to $178 per 100 Medicare services performed
Looking for a rheumatology in Houston?
Compare rheumatologys in the Houston area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
77
Per 100K population
1.6
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN MEMORIAL CITY HOSPITAL
2.4 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Abou-Khamis is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and high industry engagement (speaking/promotional, top 5%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Abou-Khamis experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Abou-Khamis performed 82,400 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abou-Khamis receive payments from pharmaceutical companies?
Yes. Dr. Abou-Khamis received a total of $174,240 from 43 companies across 1,098 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abou-Khamis's costs compare to other rheumatologys in Houston?
Dr. Abou-Khamis's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abou-Khamis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →